You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Details for New Drug Application (NDA): 213302


✉ Email this page to a colleague

« Back to Dashboard


NDA 213302 describes ATENOLOL AND CHLORTHALIDONE, which is a drug marketed by Aiping Pharm Inc, Aurobindo Pharma Usa, Nostrum Labs, Novitium Pharma, Pliva, Sun Pharm Industries, Unichem, Watson Labs, and Zydus Pharms, and is included in nine NDAs. It is available from nine suppliers. Additional details are available on the ATENOLOL AND CHLORTHALIDONE profile page.

The generic ingredient in ATENOLOL AND CHLORTHALIDONE is atenolol; chlorthalidone. There are thirty-four drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the atenolol; chlorthalidone profile page.
Summary for 213302
Tradename:ATENOLOL AND CHLORTHALIDONE
Applicant:Unichem
Ingredient:atenolol; chlorthalidone
Patents:0
Pharmacology for NDA: 213302
Mechanism of ActionAdrenergic beta-Antagonists
Physiological EffectIncreased Diuresis
Suppliers and Packaging for NDA: 213302
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ATENOLOL AND CHLORTHALIDONE atenolol; chlorthalidone TABLET;ORAL 213302 ANDA Unichem Pharmaceuticals (USA), Inc. 29300-400 29300-400-01 100 TABLET in 1 BOTTLE (29300-400-01)
ATENOLOL AND CHLORTHALIDONE atenolol; chlorthalidone TABLET;ORAL 213302 ANDA Unichem Pharmaceuticals (USA), Inc. 29300-400 29300-400-05 500 TABLET in 1 BOTTLE (29300-400-05)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength50MG;25MG
Approval Date:Nov 25, 2020TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG;25MG
Approval Date:Nov 25, 2020TE:ABRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links